RIGEL PHARMACEUTICALS INC (RIGL) Stock Fundamental Analysis
USA - NASDAQ:RIGL - US7665597024 - Common Stock
34.56 USD
-0.63 (-1.79%)
RIGL gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. Both the profitability and the financial health of RIGL get a neutral evaluation. Nothing too spectacular is happening here. RIGL has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make RIGL a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
In the past year RIGL was profitable.
In the past year RIGL had a positive cash flow from operations.
In the past 5 years RIGL reported 4 times negative net income.
In multiple years RIGL reported negative operating cash flow during the last 5 years.
1.2 Ratios
RIGL's Return On Assets of 47.32% is amongst the best of the industry. RIGL outperforms 99.62% of its industry peers.
RIGL has a Return On Equity of 119.39%. This is amongst the best in the industry. RIGL outperforms 99.25% of its industry peers.
RIGL's Return On Invested Capital of 68.80% is amongst the best of the industry. RIGL outperforms 99.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 47.32% | ||
| ROE | 119.39% | ||
| ROIC | 68.8% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RIGL's Profit Margin of 36.51% is amongst the best of the industry. RIGL outperforms 96.61% of its industry peers.
With an excellent Operating Margin value of 39.04%, RIGL belongs to the best of the industry, outperforming 98.49% of the companies in the same industry.
With an excellent Gross Margin value of 91.52%, RIGL belongs to the best of the industry, outperforming 92.47% of the companies in the same industry.
In the last couple of years the Gross Margin of RIGL has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.04% | ||
| PM (TTM) | 36.51% | ||
| GM | 91.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
2. Health
2.1 Basic Checks
RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, RIGL has more shares outstanding
RIGL has less shares outstanding than it did 5 years ago.
RIGL has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.42, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.42, RIGL perfoms like the industry average, outperforming 49.53% of the companies in the same industry.
RIGL has a debt to FCF ratio of 0.91. This is a very positive value and a sign of high solvency as it would only need 0.91 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.91, RIGL belongs to the top of the industry, outperforming 94.35% of the companies in the same industry.
A Debt/Equity ratio of 0.46 indicates that RIGL is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.46, RIGL is doing worse than 72.13% of the companies in the same industry.
Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 0.91 | ||
| Altman-Z | -2.42 |
ROIC/WACC7.81
WACC8.81%
2.3 Liquidity
A Current Ratio of 2.02 indicates that RIGL has no problem at all paying its short term obligations.
RIGL's Current ratio of 2.02 is on the low side compared to the rest of the industry. RIGL is outperformed by 74.76% of its industry peers.
A Quick Ratio of 1.90 indicates that RIGL should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.90, RIGL is doing worse than 74.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.9 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 4307.14% over the past year.
RIGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 53.38%.
RIGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.77% yearly.
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)53.38%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
3.2 Future
RIGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.86% yearly.
Based on estimates for the next years, RIGL will show a quite strong growth in Revenue. The Revenue will grow by 14.40% on average per year.
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y29.86%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y14.4%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 5.60, which indicates a rather cheap valuation of RIGL.
RIGL's Price/Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.49% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.06. RIGL is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 8.97 indicates a reasonable valuation of RIGL.
Based on the Price/Forward Earnings ratio, RIGL is valued cheaply inside the industry as 97.74% of the companies are valued more expensively.
RIGL is valuated cheaply when we compare the Price/Forward Earnings ratio to 32.73, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.6 | ||
| Fwd PE | 8.97 |
4.2 Price Multiples
98.49% of the companies in the same industry are more expensive than RIGL, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 98.31% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.42 | ||
| EV/EBITDA | 4.93 |
4.3 Compensation for Growth
RIGL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RIGL has a very decent profitability rating, which may justify a higher PE ratio.
RIGL's earnings are expected to grow with 61.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y102.44%
EPS Next 3Y61.96%
5. Dividend
5.1 Amount
No dividends for RIGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:RIGL (11/10/2025, 11:44:39 AM)
34.56
-0.63 (-1.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners80.02%
Inst Owner Change0.45%
Ins Owners2.58%
Ins Owner Change1.25%
Market Cap620.01M
Revenue(TTM)179.28M
Net Income(TTM)97.82M
Analysts76.67
Price Target39.1 (13.14%)
Short Float %19.93%
Short Ratio5.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)308.53%
Min EPS beat(2)24.64%
Max EPS beat(2)592.43%
EPS beat(4)4
Avg EPS beat(4)440.39%
Min EPS beat(4)24.64%
Max EPS beat(4)1076.54%
EPS beat(8)7
Avg EPS beat(8)241.24%
EPS beat(12)11
Avg EPS beat(12)177.31%
EPS beat(16)13
Avg EPS beat(16)133.23%
Revenue beat(2)2
Avg Revenue beat(2)15.63%
Min Revenue beat(2)12.08%
Max Revenue beat(2)19.17%
Revenue beat(4)4
Avg Revenue beat(4)17.43%
Min Revenue beat(4)9.15%
Max Revenue beat(4)29.32%
Revenue beat(8)7
Avg Revenue beat(8)9.33%
Revenue beat(12)10
Avg Revenue beat(12)13.36%
Revenue beat(16)11
Avg Revenue beat(16)9.9%
PT rev (1m)0%
PT rev (3m)13.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)256.15%
EPS NY rev (1m)0%
EPS NY rev (3m)380.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)22.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)39.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.6 | ||
| Fwd PE | 8.97 | ||
| P/S | 2.31 | ||
| P/FCF | 9.42 | ||
| P/OCF | 9.42 | ||
| P/B | 7.57 | ||
| P/tB | 11.07 | ||
| EV/EBITDA | 4.93 |
EPS(TTM)6.17
EY17.85%
EPS(NY)3.85
Fwd EY11.15%
FCF(TTM)3.67
FCFY10.61%
OCF(TTM)3.67
OCFY10.62%
SpS14.93
BVpS4.57
TBVpS3.12
PEG (NY)0.01
PEG (5Y)N/A
Graham Number25.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 47.32% | ||
| ROE | 119.39% | ||
| ROCE | 87.08% | ||
| ROIC | 68.8% | ||
| ROICexc | 704.92% | ||
| ROICexgc | N/A | ||
| OM | 39.04% | ||
| PM (TTM) | 36.51% | ||
| GM | 91.52% | ||
| FCFM | 24.56% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score6
Asset Turnover1.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 0.91 | ||
| Debt/EBITDA | 0.35 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 15.13 | ||
| Cash Conversion | 61.51% | ||
| Profit Quality | 67.26% | ||
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.9 | ||
| Altman-Z | -2.42 |
F-Score6
WACC8.81%
ROIC/WACC7.81
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y29.86%
Revenue 1Y (TTM)53.38%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y14.4%
EBIT growth 1Y1259.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year470.56%
EBIT Next 3Y88.04%
EBIT Next 5YN/A
FCF growth 1Y235.34%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y297.38%
OCF growth 3Y74.92%
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to RIGL.
Can you provide the valuation status for RIGEL PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
Can you provide the expected EPS growth for RIGL stock?
The Earnings per Share (EPS) of RIGEL PHARMACEUTICALS INC (RIGL) is expected to grow by 503.1% in the next year.